



SymBio Pharmaceuticals Limited

San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

March 9, 2009

SymBio Pharmaceuticals Limited.

Fuminori Yoshida

Representative Director
President and Chief Executive Officer

SyB L-0501 Phase II Trial Results in Low-Grade Non-Hodgkin's Lymphoma Reviewed by Independent Data Monitoring Committee

TOKYO, Japan, March 9, 2009 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio,") announced today that on March 6, Independent Data Monitoring Committee (IDMC) of SyB L-0501 held a meeting to evaluate and discuss results of a phase II clinical trial of SyB L-0501 in low-grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma. The effectiveness of SyB L-0501 in these lymphomas was objectively confirmed by third-party experts. The trial enrolled a total of 69 patients: 58 with relapsed low-grade NHL and 11 with mantle cell lymphoma. All of them were subjected to efficacy evaluation. Results of the trial are expected to be presented at the 51st annual meeting of the American Society of Hematology (ASH) to be held this year.

Because the efficacy of SyB L-0501 was confirmed by IDMC to be greater than originally expected, SymBio will pursue the preparation for filing license application before the end of this year as planned.

[SyB L-0501]

The licensor of SyB L-0501 (bendamustine hydrochloride) is Astellas Deutschland GmbH, a German affiliate of Astellas Pharma Inc. Cephalon and Mundi Pharma International Corporation Limited hold development and commercialization rights of bendamustine hydrochloride in North America and in Europe, respectively. SymBio holds exclusive rights from Astellas Deutschland GmbH to develop and market SyB L-0501 in Japan, China (HK), Taiwan, Korea and Singapore. SymBio and Eisai Co., Ltd. executed a license agreement for the co-development and commercialization of SyB L-0501 in Japan in August 2008.

[Company Profile]

SymBio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate philosophy is "delivering hope to patients in need," and the company aims to address unmet medical needs of patients in Japan and other Asia Pacific regions by cultivating a mutually beneficial or symbiotic relationship among physicians, scientists, investors, government, and patients in the healthcare industry.

[Contact]

SymBio Pharmaceuticals Limited.

IR inquiry desk, Corporate Division

Tel: +081(0)3 5472 1125

e-mail: Please send your inquiry through “INQUIRY” in our homepage

URL: <http://www.symbiosis.co.jp>